Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « AbsEn.i » - entrée « ritonavir »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
risky < ritonavir < rituximab  Facettes :

List of bibliographic references indexed by ritonavir

Number of relevant bibliographic references: 236.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000009 (2021) Rashed Noor [Bangladesh]Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.
000014 (2021) Julio Echarte-Morales [Espagne] ; Carlos Minguito-Carazo [Espagne] ; Samuel Del Castillo-García [Espagne] ; Javier Borrego-Rodríguez [Espagne] ; Miguel Rodríguez-Santamarta [Espagne] ; Enrique Sánchez-Mu Oz [Espagne] ; Rubén Bergel-García [Espagne] ; Clea González-Maniega [Espagne] ; Silvia Prieto-González [Espagne] ; Paula Menéndez-Suarez [Espagne] ; Elena Tundidor-Sanz [Espagne] ; Tomás Benito-González [Espagne] ; Felipe Fernández-Vázquez [Espagne]Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
000015 (2021) Roberto Ariel Abelda O Zu Iga [Mexique] ; Silvia Mercedes Coca [Mexique] ; Giuliana Florencia Abelda O [Mexique] ; Ruth Ana María González-Villoria [Mexique]Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis.
000076 (2021) Johanna Schneider [Allemagne] ; Bernd Jaenigen [Allemagne] ; Dirk Wagner [Allemagne] ; Siegbert Rieg [Allemagne] ; Daniel Hornuss [Allemagne] ; Paul M. Biever [Allemagne] ; Winfried V. Kern [Allemagne] ; Gerd Walz [Allemagne]Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
000103 (2021) Rana Aljadeed [Arabie saoudite] ; Yazed Alruthia [Arabie saoudite] ; Bander Balkhi [Arabie saoudite] ; Ibrahim Sales [Arabie saoudite] ; Monira Alwhaibi [Arabie saoudite] ; Omar Almohammed [Arabie saoudite] ; Abdulaziz J. Alotaibi [Arabie saoudite] ; Ali M. Alrumaih [Arabie saoudite] ; Yousif Asiri [Arabie saoudite]The Impact of COVID-19 on Essential Medicines and Personal Protective Equipment Availability and Prices in Saudi Arabia.
000111 (2021) L. Ratiani ; S. Gegechkory ; K. Machavariani ; T. Shotadze ; T. Sanikidze [Géorgie (pays)] ; N. IntskirveliTHE PECULIARITY OF COVID- 19 GENOME AND THE CORONAVIRUS RNA TRANSLATION PROCESS AS APOTENTIAL TARGET FOR ETIOTROPIC MEDICATIONSWITH ADENINE AND OTHER NUCLEOTIDE ANALOGUES (REVIEW).
000127 (2021) Thirumal Kumar D [Inde] ; Nishaat Shaikh [Inde] ; Udhaya Kumar S [Inde] ; George Priya Doss C [Inde] ; Hatem Zayed [Qatar]Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2.
000133 (2021) Isidro García-Meni O [Espagne] ; Lorena Forcelledo [Espagne] ; Yaiza Rosete [Espagne] ; Emilio García-Prieto [Espagne] ; Dolores Escudero [Espagne] ; Javier Fernández [Espagne]Spread of OXA-48-producing Klebsiella pneumoniae among COVID-19-infected patients: The storm after the storm.
000137 (2021) Ça La Begüm Apayd N [Turquie] ; Gözde Ç Nar [Turquie] ; Gökçe Cihan-Üstünda [Turquie]Small-molecule antiviral agents in ongoing clinical trials for COVID-19.
000138 (2021) Katharina Habler [Allemagne] ; Mathias Brügel [Allemagne] ; Daniel Teupser [Allemagne] ; Uwe Liebchen [Allemagne] ; Christina Scharf [Allemagne] ; Ulf Schönermarck [Allemagne] ; Michael Vogeser [Allemagne] ; Michael Paal [Allemagne]Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
000166 (2021) Giulia Fiscon [Italie] ; Federica Conte [Italie] ; Lorenzo Farina [Italie] ; Paola Paci [Italie]SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
000171 (2021) Carmen Manciuc [Roumanie] ; Dragos Nemescu [Roumanie] ; Andrei Vata [Roumanie] ; Georgiana Alexandra Lacatusu [Roumanie]SARS-CoV-2 infection and diabetes mellitus: A North Eastern Romanian experience.
000178 (2021) N. Martínez-Sánchez [Espagne] ; M. De La Calle Fernández-Miranda [Espagne] ; J L Bartha [Espagne]SAFETY PROFILE OF TREATMENTS ADMINISTERED IN COVID 19 INFECTION IN PREGNANT WOMEN.
000180 (2021) Ilad Alavi Darazam [Iran] ; Shervin Shokouhi [Iran] ; Mohamad Amin Pourhoseingholi [Iran] ; Seyed Sina Naghibi Irvani [Iran] ; Majid Mokhtari [Iran] ; Minoosh Shabani [Iran] ; Mahdi Amirdosara [Iran] ; Parham Torabinavid [Iran] ; Maryam Golmohammadi [Iran] ; Sayedpayam Hashemi [Iran] ; Arsalan Azimi [Iran] ; Mohammad Hossein Jafarazadeh Maivan [Iran] ; Omidvar Rezaei [Iran] ; Alireza Zali [Iran] ; Mohammadreza Hajiesmaeili [Iran] ; Hadiseh Shabanpour Dehbsneh [Iran] ; Akram Hoseyni Kusha [Iran] ; Maryam Taleb Shoushtari [Iran] ; Negar Khalili [Iran] ; Azam Soleymaninia [Iran] ; Latif Gachkar [Iran] ; Ali Khoshkar [Iran]Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.
000185 (2021) Sonsoles Salto-Alejandre [Espagne] ; Silvia Jiménez-Jorge [Espagne] ; Nuria Sabé [Espagne] ; Antonio Ramos-Martínez [Espagne] ; Laura Linares [Espagne] ; Maricela Valerio [Espagne] ; Pilar Martín-Dávila [Espagne] ; Mario Fernández-Ruiz [Espagne] ; María Carmen Fari As [Espagne] ; Marino Blanes-Juliá [Espagne] ; Elisa Vidal [Espagne] ; Zaira R. Palacios-Baena [Espagne] ; Román Hernández-Gallego [Espagne] ; Jordi Carratalá [Espagne] ; Jorge Calder N-Parra [Espagne] ; María Ángeles Marcos [Espagne] ; Patricia Mu Oz [Espagne] ; Jesús Fortún-Abete [Espagne] ; José María Aguado [Espagne] ; Francisco Arnaiz-Revillas [Espagne] ; Rosa Blanes-Hernández [Espagne] ; Julián De La Torre-Cisneros [Espagne] ; Luis E. L Pez-Cortés [Espagne] ; Elena García De Vinuesa-Calvo [Espagne] ; Clara M. Rosso [Espagne] ; Jer Nimo Pach N [Espagne] ; Javier Sánchez-Céspedes [Espagne] ; Elisa Cordero [Espagne]Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study.
000188 (2021) Veronique Michaud [États-Unis, Canada] ; Pamela Dow [États-Unis] ; Sweilem B. Al Rihani [États-Unis] ; Malavika Deodhar [États-Unis] ; Meghan Arwood [États-Unis] ; Brian Cicali [États-Unis] ; Jacques Turgeon [États-Unis, Canada]Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.
000215 (2021) Alexandre O. Gérard [France] ; Audrey Laurain [France] ; Audrey Fresse [France] ; Nadège Parassol [France] ; Marine Muzzone [France] ; Fanny Rocher [France] ; Vincent L M. Esnault [France] ; Milou-Daniel Drici [France]Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
000220 (2021) Mengmeng Zhao [République populaire de Chine] ; Jishou Zhang [République populaire de Chine] ; Hanli Li [République populaire de Chine] ; Zhen Luo [République populaire de Chine] ; Jing Ye [République populaire de Chine] ; Yao Xu [République populaire de Chine] ; Zhen Wang [République populaire de Chine] ; Di Ye [République populaire de Chine] ; Jianfang Liu [République populaire de Chine] ; Dan Li [République populaire de Chine] ; Menglong Wang [République populaire de Chine] ; Jun Wan [République populaire de Chine]Recent progress of antiviral therapy for coronavirus disease 2019.
000231 (2021) Venkata R. Emani [États-Unis] ; Sanjeev Goswami [États-Unis] ; Dheeraj Nandanoor [États-Unis] ; Shaila R. Emani [États-Unis] ; Nidhi K. Reddy [États-Unis] ; Raghunath Reddy [États-Unis]Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs.
000234 (2021) Carlos Diaz-Arocutipa [Pérou] ; Ana Bra Ez-Condorena [Pérou] ; Adrian V. Hernandez [Pérou, États-Unis]QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
000260 (2021) Keisuke Kuroda [Japon] ; Cong Li [Japon] ; Kiran Dhangar [Inde] ; Manish Kumar [Inde]Predicted occurrence, ecotoxicological risk and environmentally acquired resistance of antiviral drugs associated with COVID-19 in environmental waters.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "ritonavir" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "ritonavir" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    ritonavir
}}

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021